212 Pb ADVC 001
Alternative Names: 212-lead ADVC 001; 212Pb ADVC001; [212Pb]Pb-ADVC001Latest Information Update: 16 Jun 2026
At a glance
- Originator Advancell
- Class Antineoplastics; Lead radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 08 Jun 2026 Advancell plans a phase III trial in Prostate cancer
- 12 Feb 2026 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, In adults, In the elderly, Metastatic disease, Second-line therapy or greater) is underway in Australia (IV) (NCT05720130)
- 02 Feb 2026 AdvanCell and 48Hour Discovery agree to co-develop a novel peptide-based Lead-212 radiotherapeutic for Gastrointestinal cancer